CompletedNCT04829318
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
Medication studyAges 18–74Multiple countriesDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 74 years.
- Listed locations
- Buenos Aires and 58 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: April 26, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 183
- Sponsor
- Janssen-Cilag Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium, Argentina, Bulgaria, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT04829318
- Official title
Show the full official title
Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
Get this study by email
Recruitment & locations
CompletedBuenos Aires, Argentina · Córdoba, Argentina · La Plata, Argentina
45 more locations
- Rosario, Argentina
- Alken, Belgium
- Rousse, Bulgaria
- Sofia, Bulgaria
- Brno, Czechia
- Hradec Králové, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Helsinki, Finland
- Berlin, Germany
- Dortmund, Germany
- Freiburg im Breisgau, Germany
- Hamburg, Germany
- Hennigsdorf, Germany
- Mittweida, Germany
- Pfaffenhofen, Germany
- Schwerin, Germany
- Heraklion, Greece
- Pátrai, Greece
- Thessaloniki, Greece
- Budapest, Hungary
- Gyöngyös, Hungary
- Győr, Hungary
- Ipoh, Malaysia
- Kuala Lumpur, Malaysia
- Serdang, Malaysia
- Seremban, Malaysia
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Katowice, Poland
- Leszno, Poland
- Lodz, Poland
- Torun, Poland
- Cape Town, South Africa
- Pretoria, South Africa
- Seoul, South Korea
- Changhua, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Ankara, Türkiye
- Istanbul, Türkiye
- Samsun, Türkiye
- Czechia
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag Ltd.
Did this study involve medication?
Yes. The study involved medication, including Esketamine and SSRI/SNRI.
Who was this study for?
Listed age limits: 18 years to 74 years.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide